Clinical Studies
Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
Obesity/Weight Management
Women's Health
Other
Special Features
Advances/Research
Double-Blind, Placebo-controlled Study of Escitalopram in the Treatment of Dysthymic Disorder
| Time frame of study: | March 2003-September 2006 | |
| Number of participants needed | 40 | |
| Time frame of participation: | 6 months | |
| Location of Study: |
Mood Disorders
Research Program |
|
| Contact Name and Number: | Sarai
Batchelder, PhD 212-523-7666 or email sbatchel@chpnet.org |
Summary:
The Mood Disorders Research Unit at Roosevelt Hospital, in conjunction with researchers at New York State Psychiatric Institute, is conducting a 6-month study of a recently FDA-approved antidepressant medication. We are testing whether this medication is effective for the treatment of Dysthymic Disorder, which is a form of chronic depression. The study involves a 12-week double-blind phase during which half the subjects will take the new medication and half will take a placebo (an inactive look-alike pill). After the first 12 weeks, you will learn what you have been taking, and a second 12-week phase will begin during which you will be treated with an FDA-approved, antidepressant medication.
If you are between
18 and 65 years old, and have been feeling down, sad, listless, unable
to enjoy things, hopeless, or low in self esteem for at least several
years, you may have Dysthymic Disorder and may qualify to participate
in our medication study. All study-related evaluations, laboratory tests,
medication, and visits are free of charge.
Criteria
for Participation:
Patients
with recent drug abuse or dependence, requiring other psychotropic medications
during the study, a history of Bipolar disorder, Schizophrenia, or Schizoaffective
Disorder, or who have significant and unstable medical problems (for example:
uncontrolled hypertension, uncontrolled diabetes, HIV or AIDS, among others)
are not eligible.